Workpackage 13 – Guidelines
The development of clinical guidelines and care pathways is crucial to improve the access to diagnosis and treatment. Guideline development was a key deliverable of E-pilepsy; such will be essential to the provision of high-quality healthcare to all patients with rare and complex epilepsies. Guidelines should also be focal points for medical training and research. We will continue to use a transparent methodology (Grading of Recommendations Assessment, Development and Evaluation; GRADE) in order to ensure implementation of all available evidence, and involvement of all stakeholders. All developments will follow the rules of the GRADE Methodology, which uses the best available evidence along with expert opinion and patient representatives to develop explicit criteria to guide clinical care. Systematic reviews of relevant evidence will thus precede all further activities in this WP and will underpin all medical information, procedures, and applications developed in EpiCARE.
- To identify international epilepsy clinical care guidelines and assess their quality by using a systematic methodology.
The EpiCARE Guideline Development Group conducted a survey with the aim to evaluate the current state of the guidelines being used by centres of the EpiCARE network for diagnosis and treatment of rare and complex epilepsies. The guideline group is currently assessing the quality of collected documents by using the AGREE II tool. The results of the survey will be published in due course.
“Epilepsies in children and young people: Investigative procedures and management” is the new guideline reflecting the most recent evidence around key issues and replaces SIGN 81.
- To assess adherence to existing guidelines in Centres of the European Pilot reference Network E-pilepsy and the EpiCARE network
- To determine gaps in areas of need of development of guidelines in epilepsy care of rare and complex drug resistant epilepsies, by undertaking systematic reviews of the relevant topics at stake
- To develop clinical care guidelines together with the relevant medical societies and representatives of health care providers and patient groups
- D13.1 Timeline for systematic reviews years 2-5
- D III.3 Systematic reviews on most topics with other workpackages at month 48
- D II.4 Audit on the adherence to clinical care guidelines and pathways at month 60
- M 3 Systematic reviews on available evidence
- M 14 Clinical Care Guidelines for diagnosis, evaluation and management of rare epilepsies available most centers of the EpiCARE network
Pr. Eugen Trinka, MD, MSc
Pr. Eugen Trinka, MD, MSc
Dr. Nicola Specchio, MD, Phd
Dr. Federico Vigevano